PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10394017-2	1999	Amphotericin B Colloidal Dispersion (ABCD, AmphocilTM), a noncovalent complex of amphotericin B and cholesteryl sulfate, is active in vitro and in vivo against a wide variety of fungal species; its activity is broadly comparable to the range of activity of conventionally formulated amphotericin B (CAB).	Amphotericin B	0-14	neural proliferation, differentiation and control 1	Homo sapiens	299-302	
10394017-2	1999	Amphotericin B Colloidal Dispersion (ABCD, AmphocilTM), a noncovalent complex of amphotericin B and cholesteryl sulfate, is active in vitro and in vivo against a wide variety of fungal species; its activity is broadly comparable to the range of activity of conventionally formulated amphotericin B (CAB).	Amphotericin B	81-95	neural proliferation, differentiation and control 1	Homo sapiens	299-302	
24187506-1	2013	BACKGROUND: Lipid-based formulations of amphotericin B (LF-AMB) are indicated for treatment of invasive fungal infections in patients intolerant to conventional amphotericin B (CAB) or with refractory infections.	Amphotericin B	40-54	neural proliferation, differentiation and control 1	Homo sapiens	177-180	
24187506-13	2013	CONCLUSION: Among patients at risk for amphotericin B toxicity, differences between CAB and LF-AMB seen in crude outcomes analyses relate to channeling of sicker patients to initiate treatment with LF-AMB.	Amphotericin B	39-53	neural proliferation, differentiation and control 1	Homo sapiens	84-87	
23946621-11	2013	Compared with the LF-AMB group, the CAB/LF-AMB patients had a longer post-amphotericin B LOS (24.1 days vs. 15.7 days, respectively; P < 0.001), with a marginal effect of 4.5 days longer for those receiving CAB/LF-AMB (P = 0.016).	Amphotericin B	74-88	neural proliferation, differentiation and control 1	Homo sapiens	36-39